1,763 Intuitive Surgical, Inc. $ISRG Shares Sold by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 191,661 shares of the medical equipment provider’s stock after selling 1,763 shares during the period. Intuitive Surgical makes up approximately 1.5% of Bank Pictet & Cie Europe AG’s investment portfolio, making the stock its 18th biggest position. Bank Pictet & Cie Europe AG owned 0.05% of Intuitive Surgical worth $77,935,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ISRG. North Point Portfolio Managers Corp OH bought a new position in Intuitive Surgical during the third quarter valued at approximately $27,000. Main Street Group LTD purchased a new position in Intuitive Surgical during the 1st quarter valued at approximately $30,000. Compass Financial Management LLC bought a new stake in Intuitive Surgical in the 2nd quarter worth approximately $30,000. Vermillion Wealth Management Inc. increased its stake in Intuitive Surgical by 58.1% in the 1st quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 25 shares during the last quarter. Finally, Evergreen Advisors LLC bought a new stake in Intuitive Surgical in the 1st quarter worth approximately $35,000. 83.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Royal Bank Of Canada lowered their target price on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Oppenheimer raised shares of Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 target price for the company in a report on Wednesday, August 12th. UBS Group restated a “buy” rating on shares of Intuitive Surgical in a research report on Tuesday, October 13th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Finally, Robert W. Baird lowered their price objective on shares of Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating for the company in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $498.83.

Insider Activity

In other news, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $379.00, for a total transaction of $151,600.00. Following the transaction, the executive vice president owned 5,320 shares of the company’s stock, valued at approximately $2,016,280. This represents a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary S. Guthart sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total value of $4,000,000.00. Following the completion of the sale, the director owned 1,245,679 shares in the company, valued at approximately $498,271,600. The trade was a 0.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock worth $4,891,989 in the last 90 days. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical Stock Performance

ISRG stock traded up $3.42 during mid-day trading on Tuesday, reaching $436.60. 937,028 shares of the stock traded hands, compared to its average volume of 2,402,207. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88. The stock has a market capitalization of $154.24 billion, a PE ratio of 50.07, a PEG ratio of 3.22 and a beta of 1.46. The business has a 50-day moving average price of $392.22 and a two-hundred day moving average price of $409.24.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: TD Cowen maintained a Buy rating and a $485 price target, citing robust demand for robotic surgery and potential upside relative to conservative forecasts. Analyst Maintains Buy on Robust Robotic Demand
• Positive Sentiment: Investors continue to see a strong long-term growth case as da Vinci 5 placements rose to 246 in the second quarter from 180 a year earlier, while procedures increased about 15%. Intuitive’s recurring revenue from instruments, accessories and servicing also expands with procedure volume. The Bull Case for Intuitive Surgical
• Neutral Sentiment: Attention is centered on the earnings release after market close. The market expects revenue growth of approximately 15.6% year over year, below the 22.9% growth recorded in the comparable period last year, while analyst estimates have remained largely unchanged. Bull Case Could Change Following Earnings
• Neutral Sentiment: Intuitive plans to extend instrument life in 2027, potentially lowering procedure costs and broadening adoption of robotic surgery. However, management expects to trade some near-term revenue per procedure for longer-term utilization and market expansion. Why ISRG Is Lowering Instrument Costs
• Negative Sentiment: The primary risk is that moderating revenue growth, evolving procedure mix and Intuitive’s premium valuation could make the stock more sensitive to any earnings or outlook disappointment.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.